The FDA delivered a Form 483 to a clinical trial director after an investigation revealed failures to monitor the study’s progress and to obtain required statements from investigators.
Source: Clinical Trials Advisor
The FDA delivered a Form 483 to a clinical trial director after an investigation revealed failures to monitor the study’s progress and to obtain required statements from investigators.
Source: Clinical Trials Advisor